Ashok Shok Gupta

US Patent:

20130309250, Nov 21, 2013

Filed:

May 13, 2013

Appl. No.:

13/892671

Inventors:

Stacie M. Goldberg - Princeton NJ, US
Ashok K. Gupta - Plainsboro NJ, US
Xi Tao Wang - Wellesley MA, US
John M. Wigginton - Collegeville PA, US

International Classification:

C07K 16/28

US Classification:

4241721, 5303882

Abstract:

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

US Patent:

20220332828, Oct 20, 2022

Filed:

Apr 14, 2022

Appl. No.:

17/720903

Inventors:

- GAITHERSBURG MD, US
JOHN ANDREW BLAKE-HASKINS - GAITHERSBURG MD, US
MAGDALENA ZAJAC - CAMBRIDGE, GB
MARLON REBELATTO - GAITHERSBURG MD, US
ASHOK GUPTA - GAITHERSBURG MD, US
TONY HO - GAITHERSBURG MD, US
JILL WALKER - CAMBRIDGE, GB
XIAOPING JIN - GAITHERSBURG MD, US
SHANNON MORRIS - GAITHERSBURG MD, US
ROBERT IANNONE - GAITHERSBURG MD, US
LI SHI - GAITHERSBURG MD, US
MOHAMMED DAR - GAITHERSBURG MD, US
YONG BEN - GAITHERSBURG MD, US

International Classification:

C07K 16/28
A61P 35/00
A61K 9/00
G01N 33/542

Abstract:

Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.

US Patent:

20200308282, Oct 1, 2020

Filed:

Mar 23, 2020

Appl. No.:

16/827580

Inventors:

- Princeton NJ, US
Stacie M. Goldberg - Potomac MD, US
Ashok K. Gupta - Clarksburg MD, US
Xi-Tao Wang - Wellesley MA, US
Jon M. Wigginton - Collegeville PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
A61K 39/395
C07K 16/18
G01N 33/574

Abstract:

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

US Patent:

20190359715, Nov 28, 2019

Filed:

Feb 16, 2018

Appl. No.:

16/486222

Inventors:

- GAITHERSBURG MD, US
JOHN ANDREW BLAKE-HASKINS - GAITHERSBURG MD, US
MAGDALENA ZAJAC - CAMBRIDGE, GB
MARLON REBELATTO - GAITHERSBURG MD, US
ASHOK GUPTA - GAITHERSBURG MD, US
TONY HO - GAITHERSBURG MD, US
JILL WALKER - CAMBRIDGE, GB
XIAOPING JIN - GAITHERSBURG MD, US
SHANNON MORRIS - GAITHERSBURG MD, US
ROBERT IANNONE - GAITHERSBURG MD, US
LI SHI - GAITHERSBURG MD, US
MOHAMMED DAR - GAITHERSBURG MD, US
YONG BEN - GAITHERSBURG MD, US

International Classification:

C07K 16/28
A61K 9/00
G01N 33/542
A61P 35/00

Abstract:

Provided are methods of treating bladder cancer (e.g., urothelial carcinoma, UC) in a subject having bladder cancer, e.g., UC, with an effective dose regimen of an anti-PD-L1 antibody, e.g., durvalumab, or an antigen binding fragment thereof. Also provided are methods in which an anti-PD-L1 antibody is used in combination with another immunotherapeutic agent, e.g., tremelimumab to treat a bladder cancer, e.g., UC, in a subject having bladder cancer. In some cases, the subject undergoing treatment is identified as having a bladder cancer or tumor that is PD-L1-low/neg, or PD-L1-high. Methods are also provided in which anti-PD-L1 antibody treatment of bladder cancer is used following a standard of care or first-line therapy in subjects who have progressed following such therapies or who have relapsed after a prior treatment regimen.

US Patent:

20190153099, May 23, 2019

Filed:

Jan 15, 2019

Appl. No.:

16/248215

Inventors:

- Princeton NJ, US
Stacie M. Goldberg - Potomac MD, US
Ashok K. Gupta - Clarksburg MD, US
Xi-Tao Wang - Wellesley MA, US
Jon M. Wigginton - Collegeville PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
A61K 39/395
C07K 16/18
G01N 33/574

Abstract:

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

US Patent:

20190112376, Apr 18, 2019

Filed:

Dec 21, 2018

Appl. No.:

16/230657

Inventors:

- Princeton NJ, US
Stacie M. Goldberg - Potomac MD, US
Ashok K. Gupta - Clarksburg MD, US
Xi-Tao Wang - Wellesley MA, US
Jon M. Wigginton - Collegeville PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
A61K 39/395
C07K 16/18
G01N 33/574

Abstract:

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

US Patent:

20190112377, Apr 18, 2019

Filed:

Dec 21, 2018

Appl. No.:

16/231211

Inventors:

- Princeton NJ, US
Stacie M. Goldberg - Potomac MD, US
Ashok K. Gupta - Clarksburg MD, US
Xi-Tao Wang - Wellesley MA, US
Jon M. Wigginton - Collegeville PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
A61K 39/395
C07K 16/18
G01N 33/574

Abstract:

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

US Patent:

20190100589, Apr 4, 2019

Filed:

Dec 7, 2018

Appl. No.:

16/213954

Inventors:

- Princeton NJ, US
Stacie M. Goldberg - Potomac MD, US
Ashok K. Gupta - Clarksburg MD, US
Xi-Tao Wang - Wellesley MA, US
Jon M. Wigginton - Collegeville PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
G01N 33/574
C07K 16/18
A61K 39/395

Abstract:

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.